Proposed legislation that would allot $8.75 billion in new NIH grants over the next five years comes at a cost that’s too high in the eyes of critics. They say the bill, backed by the pharmaceutical, biotechnology and medical-device industries, would weaken Food and Drug Administration scrutiny and jeopardize patient safety. Jerry Avorn, professor of medicine at Brigham and Women’s Hospital, is quoted.
Trending News
Research Provides Clues to Spleen’s Role in Coronary Artery Disease
Genetic variants may drive visible changes in the spleen that contribute to heart disease
Patient Who Received Pig Kidney Becomes First To Progress to Human Kidney Transplant
Study shows xenotransplantation can serve as a bridge for patients with end-stage kidney disease
Pilots, Flight Attendants Have Greater Risk of Radiation-Related Cancer Death Than Other Professions
Findings support efforts to protect U.S. aircrews from cosmic radiation exposure